Design and synthesis of novel α(1a) adrenoceptor-selective dihydropyridine antagonists for the treatment of benign prostatic hyperplasia

Journal of Medicinal Chemistry

Volumn 41, Issue 26, 1998, Pages 5320-5333

  Nagarathnam, Dhanapalan ^a   Wetzel, John M ^a   Miao, Shou Wu ^a   Marzabadi, Mohammad R ^a   Chiu, George ^a   Wong, Wai C ^a   Hong, Xingfang ^a   Fang, James ^a   Forray, Carlos ^a   Branchek, Theresa A ^a   Heydorn, William E ^a   Chang, Raymond S L ^b   Broten, Theodore ^b   Schorn, Terry W ^b   Gluchowski, Charles ^a  

^a H LUNDBECK A S   (Denmark)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 3 [N [(4 (METHOXYCARBONYL) 4 PHENYLPIPERIDIN 1 YL)PROPYL]CARBOXAMIDO] 5 (N METHYLCARBOXAMIDO) 4 (4 NITROPHENYL)PYRIDINE; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; PRAZOSIN; PYRIDINE DERIVATIVE; TERAZOSIN; UNCLASSIFIED DRUG;

ALPHA ADRENERGIC RECEPTOR BLOCKING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DOG; DRUG DESIGN; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PROSTATE HYPERTROPHY;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BINDING, COMPETITIVE; BLOOD PRESSURE; CELL LINE; DIHYDROPYRIDINES; DOGS; DRUG EVALUATION, PRECLINICAL; HUMANS; MALE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PIPERIDINES; PROSTATE; PROSTATIC HYPERPLASIA; RATS; RECEPTORS, ADRENERGIC, ALPHA-1; RECOMBINANT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032542265     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980506g     Document Type: Article

References (26)

1. Geller, J.; Kirschenbaum, A.; Lepor, H.; Levine, A. C. Therapeutic Controversies: Clinical Treatment of Benign Prostatic Hyperplasia. J. Clin. Endocrinol. Metab. 1995, 80, 745-747.
2. Garraway, W. M.; Collins, G. N.; Lee, R. J. High Prevalence of Benign Prostatic Hypertrophy in the Community. Lancet 1991, 338, 469-471.
3. Monda, J. M.; Oesterling, J. E. Medical Management of Benign Prostatic Hyperplasia. Infect. Urol. 1994, 47-59.
4. Lepor, H. Role of Alpha-Adrenergic Blockers in the Treatment of Benign Prostatic Hyperplasia. Prostate Suppl. 1990, 3, 75-84.
5. Jankegt, R. A.; Chapple, C. R. Efficacy and safety of the Alpha-1 Blocker Doxazosin in the Treatment of Benign Prostatic Hyperplasia. Analysis of 5 Studies. Eur. Urol. 1993, 24, 319-325.
6. Lepor, H. Long-Term Efficacy and Safety of Terazosin in Patients with Benign Prostatic Hyperplasia. Urology 1995, 45, 406-413.
7. 1-Adrenoceptors: Consensus Update. Pharmacol. Rev. 1995, 47, 267-270.
8. 1d receptor subtypes.
9. 1c subtype. Mol. Pharmacol. 1994, 45, 703-708.
10. 1c-Adrenergic Antagonists and Orthostatic Hypotension in the Rat. FASEB J. 1994, 8, A353.
11. Kawabe, K.; Ueno, A.; Takimoto, Y.; Aso, Y.; Kato, H. Use of an Alpha-1 blocker, YM617, in the Treatment of Benign Prostatic Hypertrophy. J. Urol. 1990, 144, 908-912.
12. 1-adrenoceptor in human prostate. Eur. J. Pharmacol. 1997, 331, 39-42.
13. 1-Adrenoceptor Antagonists. J. Med. Chem. 1997, 40, 2674-2687.
14. 2+ Channel Antagonist Niguldipine. J. Med. Chem. 1995, 38, 1579-1581.
15. 1a Adenoceptor Selective Antagonist that Inhibits Phenylephrine-Induced Contraction of the Human Prostate. J. Med. Chem. 1998, 41, 2643-2650.
16. Marzabadi, M. R.; Hong, X.; Gluchowski, C. A Double Protection Methodology for the Synthesis of 3,5-Disubstituted Dihydropyridines. Tetrahedron Lett. 1998, 39, 5293-5296.
17. Bates, R. J.; Cymerman-Craig, J.; Moyie, M.; Yong, T. J. 78. A Novel Method of Cyanoethylation. Part IV. Substitution Effects. J. Chem. Soc. 1956, 388.
18. 2b-Adrenergic Receptor. Mol. Pharmacol. 1990, 38, 681-688.
19. 3H]Nitrendipine, to Guinea-Pig Ileal Smooth Muscle. J. Pharmacol. Exp. Ther. 1983, 225, 291-309.
20. 3H]mepyramine binding of brain membranes. J. Neurochem. 1979, 32, 1653-1663.
21. 3H-tiotidine to histamine H2 receptors in guinea pig cerebral cortex. Nature 1983, 304, 65-67.
22. Fargin, A.; Raymond, J.; Lohse, M.; Kobilka, B.; Caron, M.; Lefkowitz, R. The genomic clone G-21, which resembles the α-adrenergic receptor sequence, encodes the 5-HT1a receptor. Nature 1988, 335, 358-360.
23. 1Dβ. Proc. Natl. Acad. Sci. U.S.A. 1992, 3630-3634.
24. 3H]-Ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor. Mol. Pharmacol 1990, 38, 604-609.
25. 125I]L-762,459, A Selective Alpha-1A Radioligand, to Rat and Human Tissues. Eur. J. Pharmacol. 1998, 348, 287-295.
26. Arulaksana, O.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959, 14, 48-58.